All News
A possible curative therapy of an autoimmune disease via selective depletion of a TRBV-defined group of T cells. This could be potentially applicable to other HLA-B*27-associated spondyloarthropathies. Year in review, Seo #ACR23 @RheumNow https://t.co/NxxkpJhweH. https://t.co/41Po5CHid3
Dr. Antoni Chan ( View Tweet)
YR in Review: Dr. Seo
🚩GLORIA Trial
RA pts > 65yo: prednisolone 5 mg/d x 2 yrs vs PBO + std care
➡️decr dz activity (DAS ⬇️0.37) but 24% incr ADE
🚩Extension:
➡️Tapered off pred over 3m and..
⭐️NO ADRENAL INSUFF
But, small incr in dz activity (DAS ⬆️0.23)
#ACR23 @RheumNow https://t.co/YQbS6C8ZT5
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR23 Memorable Quote as reminded to us by Dr. P Seo during Year in Review:
"What you think of as a rare manifestation of a common disease is probably a common presentation of a disease you are not aware of (yet)!"
- Prof Seza Zen, MD
@RheumNow https://t.co/Xhwb1brLKG
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Yet another (mostly) reassuring report about lymphoma and DMARDS
The skin cancer signal in the CIRT trial was weird; would be worth looking into that in observational studies as well @NamrataRheum
#ACR23 Abst0438 @RheumNow https://t.co/Beg8UUe2mn
Mike Putman EBRheum ( View Tweet)
It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA.
Why is it hard? I guess:
- theory ≠ practice
- too many other factors
- it's too easy not to
Yet I hope/believe, one day we'll do better.
#ACR23 ABST0427 @RheumNow https://t.co/5VBVp3KOJN
David Liew drdavidliew ( View Tweet)
If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year?
US Medicare data 2008-17
n=33,373
only 30% have a DMARD on file
(of which bDMARD <10%)
>5% on PNL alone
Do we hate old people with RA?😔
@JihaRheum #ACR23 ABST0433 @RheumNow https://t.co/1CUXAh3fi0
David Liew drdavidliew ( View Tweet)
Revisiting question in #painful #knee #osteoarthritis Which #steroid to inject - esp with #triamcinolone #hexacetonide shortages which is superior to #acetonide. New extended release #fluticasome #propionate > #placebo ? Is how about vs IA steroids LB04 @RheumNow @ACRheum #ACR23 https://t.co/qJazwihSe0
Janet Pope ( View Tweet)
Kudos @AlexisOgdie & co for their work in this area
Given proliferation of database research for causal inference, super important to have validated criteria to identify diseases
Many spaces (looking at you sarcoidosis) where this is almost entirely absent
@RheumNow #ACR23 https://t.co/krkgWAhjMr
Mike Putman EBRheum ( View Tweet)
#obesity is a significant RF for #osteoarthritis
Assoc'd with:
💠impairment of gut biota
💠microbial translocation
Leads to innate immune activation
#ACR23 @RheumNow @rheumarhyme https://t.co/iuEvBh3A1j
sheila ( View Tweet)
I underestimated how much joy not-bankrupting our healthcare system would bring me
ADA & RTX biosimilars have been wonderful; excited for IL6's to join the party
@RheumNow #ACR23 Abstr0445 https://t.co/HGwi37rZpd
Mike Putman EBRheum ( View Tweet)
Which to use in #EGPA? #Mepolizumab IL5i vs Benralizumab = monoclonal Ab binding to IL5Ralpha. Noninferiority RCT - both are similar. Is more Impt ? IL5 drug vs #Rituximab or #Cyclo for severe Eosinoph granuloma todos w polyangiitis 🤷 #ACR23 @RheumNow @ACRheum https://t.co/zyZeHHSsck
Janet Pope ( View Tweet)
Contributing Factors for Difficult-to-Treat RA using Natural Language Processing (NLP): joint erosions (OR 2.97 CI95% [2.17; 4.08], p< 0.001) , higher disease activity (median DAS28 3.16 vs 2.89) associated with D2T, Bergier Abst#0383 #ACR23 @RheumNow https://t.co/KARxoa2Z7H
Dr. Antoni Chan ( View Tweet)
COVID boosters in RA patients:
getting the job done (versus healthy controls, irrespective of non-withheld DMARDs excluding ritux)
@UChicagoMed #ACR23 ABST0416 @RheumNow https://t.co/HVRjC4dauw
David Liew drdavidliew ( View Tweet)
I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvious dose response w 15 and 30 mg daily but more #acne at higher dose. #ACR23 @ACRheum @RheumNow poster L12 Where to use vs #Deucravitinib? Too early to say as Ph2 https://t.co/nMkgOlUf6s
Janet Pope ( View Tweet)
Does knowing ischemic stroke subtypes among SLE patients matter?
This study by Hopia et al 👉54% of ischemic strokes in 56 SLE pts were APS/aPL & cardioembolic origin (accdg to TOAST) & +assoc with STAT4 gene.
#ACR23 ABST0579 @RheumNow https://t.co/Ut8QPpQNQp
sheila ( View Tweet)
Can a picture tell a RA swollen joint?
(would be super useful for telehealth/remote monitor if so)
It's not prime time yet, but following with interest:
using photos to pick up on skin folds/joint swelling
Fascinating, but let's see it vs MRI, clinical
#ACR23 ABST0402 @RheumNow https://t.co/TFKiD5J4c8
David Liew drdavidliew ( View Tweet)
We gotta do better! Reproductive health counseling is poorly done- only a third rheumatologists surveyed ask pts about reproductive health: sexual activity, pregnancy desire, contraception. Abstr#0162 @_michgarcia @rheumnow #ACR23 https://t.co/r9tewu2I9N
TheDaoIndex KDAO2011 ( View Tweet)
Smartwatches to measures axSpA activity?
Upadacitinib use in axSpA INCREASED physical activity based on a wearable medical device step count, especially in those who were originally sedentary.
@RheumNow #ACR23 Abs#0530
#ACRbest https://t.co/oOFiQwMFZ6
Robert B Chao, MD ( View Tweet)
SLE pts with +aCL IgG/IgM and LA had higher risk of developing atherosclerotic CVD accdg to this prospective study by Ding et al.
. . .
🧐Again, SLE pts have ⬆️CV risk so always risk stratify and intervene early.
#ACR23 ABST0552 @RheumNow https://t.co/QhttQZzp8G
sheila ( View Tweet)
Year in Review by Dr. P Seo
NORD-STAR trial:
⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results
➡️tx-naive, all got MTX
➡️mod-sev dz activity
➡️randomized to 48 wks therapy
#ACR23 @RheumNow https://t.co/vy2uYuyOse
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)